Mucormycosis and COVID
Mucormycosis is uncommon and is largely confined to patients with serious pre-existing diseases Mucormycosis originating in paranasal sinuses and nose predominantly affects patients with poorly controlled diabetes mellitus. Patients who have undergone organ transplantation, who have a hematologic malignancy or who are receiving long-term deferoxamine therapy are predisposed to mucormycosis of either sinus or lung. The survival rate is found to be rare among patients who have received deferoxamine and among those with pulmonary, gastrointestinal or disseminated mucormycosis In all forms of mucormycosis, vascular invasion by hyphae is found to be a prominent feature. It has been suggested that the regulation of diabetes mellitus and a decrease in the dose of immune-suppressive drugs facilitate treatment. Intravenous amphotericin B has been found to be clearly of value. Although immune-suppressants will weaken the defence mechanism of the body and make it difficult to recover, but the p